Gold prices slip as stronger dollar, Fed rate uncertainty weigh
LONDON - Genedrive plc (AIM:GDR), a point-of-care pharmacogenetic testing company, is in discussions with major shareholder David Nugent regarding a potential loan of up to £1 million, according to a press release statement issued Today.
Nugent, who holds a 16% stake in the company both directly and through a limited company, has indicated willingness to provide the cash injection on terms that have yet to be finalized.
The discussions follow Genedrive’s general meeting held on October 15, 2025, after which the company continued engaging with Nugent about potential financing options.
Genedrive stated it welcomes this indication of potential additional financial support, though it cautioned that there is no certainty the funding will materialize.
The company plans to make further announcements regarding the potential shareholder loan as discussions progress.
Genedrive did not disclose specific terms or conditions of the proposed loan agreement, nor did it provide details about how any potential funds would be utilized.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.